Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Change in Accured Expenses (2017 - 2020)

Historic Change in Accured Expenses for Monopar Therapeutics (MNPR) over the last 4 years, with Q3 2020 value amounting to -$21418.0.

  • Monopar Therapeutics' Change in Accured Expenses rose 8345.03% to -$21418.0 in Q3 2020 from the same period last year, while for Sep 2020 it was $114857.0, marking a year-over-year increase of 32598.0%. This contributed to the annual value of $506791.0 for FY2024, which is 13800.35% up from last year.
  • Monopar Therapeutics' Change in Accured Expenses amounted to -$21418.0 in Q3 2020, which was up 8345.03% from $163152.0 recorded in Q2 2020.
  • In the past 5 years, Monopar Therapeutics' Change in Accured Expenses ranged from a high of $304229.0 in Q4 2019 and a low of -$331106.0 during Q1 2020
  • For the 4-year period, Monopar Therapeutics' Change in Accured Expenses averaged around $25946.9, with its median value being $32544.0 (2018).
  • Examining YoY changes over the last 5 years, Monopar Therapeutics' Change in Accured Expenses showed a top increase of 88914.9% in 2019 and a maximum decrease of 105056.9% in 2019.
  • Quarter analysis of 4 years shows Monopar Therapeutics' Change in Accured Expenses stood at -$26070.0 in 2017, then skyrocketed by 436.24% to $87658.0 in 2018, then soared by 247.06% to $304229.0 in 2019, then tumbled by 107.04% to -$21418.0 in 2020.
  • Its Change in Accured Expenses was -$21418.0 in Q3 2020, compared to $163152.0 in Q2 2020 and -$331106.0 in Q1 2020.